Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

NCT05265793 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

45

Enrollment

OTHER

Sponsor class

Conditions

PD-1 Immunotherapy
VEGFR-TKI
Sarcomatoid Carcinoma
Carcinosarcoma

Interventions

DRUG: Camrelizumab Combined With Apatinib

Sponsor

Fudan University